<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03641209</url>
  </required_header>
  <id_info>
    <org_study_id>39/2018</org_study_id>
    <nct_id>NCT03641209</nct_id>
  </id_info>
  <brief_title>Extremely Low Gestatonal Age Infants' Paracetamol Study</brief_title>
  <acronym>Paras</acronym>
  <official_title>Extremely Low Gestational Age Infants' Paracetamol Study: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outi Aikio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present trial, early, intravenous paracetamol is compared to placebo in extremely
      premature or low birth weight infants in order to evaluate the effect on ductal closure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, placebo-controlled, double-blind, phase 2, one center
      clinical trial is to study the efficacy and safety of early (&lt; 96 h) intravenous paracetamol
      in prophylactic closure of ductus arteriosus in extremely premature (gestational age &lt;28+0
      wk, ELGA) or low birth weight (&lt;1000 g, ELBW) infants. The infants born extremely preterm or
      low birth weight are a focus of the study, since a small phase 2 study on paracetamol failed
      to demonstrate contraction of ductus arteriosus.

      In the investigator's previous cohort of ELGA/ELBW infants, the numbers of patients who
      needed any therapies for patent ductus arteriosus (PDA) were 29 (23%) in the paracetamol
      exposed group, and 90 (54%) in the control group. As demonstrated in a phase 2 study, the
      early paracetamol treatment induced the closure of ductus arteriosus: the mean (SD) ductal
      closure age was 177 (338) h in the whole paracetamol group. However, in the subgroup of ELGA
      infants born before 28 gestation weeks (n=14), the mean (SD) ductal closure ages in the
      paracetamol and placebo groups were 491 (504) h and 858 (719) h, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, one center trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Placebo, 0.45 % saline, is similar to paracetamol, both being clear liquids, so the staff will remain unaware which drug the patient receives. The study drug will be kept and prepared away from the NICU, at the separate ward 55 office, in a locked cabinet. The study drug will be prepared by the research nurse, the pharmacist of the ward, or during nighttime, by a nurse who does not participate in the study patients' treatment in any way.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ductal closure</measure>
    <time_frame>Neonatal intensive care unit (NICU) treatment period up to 13 weeks</time_frame>
    <description>Postnatal age of the observed closure of ductus arteriosus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Near-infrared spectroscopy values</measure>
    <time_frame>Study drug period up to 10 days</time_frame>
    <description>Near-infrared spectroscopy values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol serum levels</measure>
    <time_frame>Study drug period up to 10 days</time_frame>
    <description>Paracetamol serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol side effects</measure>
    <time_frame>Neonatal intensive care unit (NICU) treatment period up to 13 weeks</time_frame>
    <description>Any observed or detected paracetamol side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDA</measure>
    <time_frame>Neonatal intensive care unit (NICU) treatment period up to 13 weeks</time_frame>
    <description>Open ductus arteriosus without any traditional PDA therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDA, treated</measure>
    <time_frame>Neonatal intensive care unit (NICU) treatment period up to 13 weeks</time_frame>
    <description>The need for PDA therapies (ibuprofen, paracetamol, ligation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory assist</measure>
    <time_frame>Neonatal intensive care unit (NICU) treatment period up to 13 weeks</time_frame>
    <description>The duration of any ventilation assist, days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of prematurity</measure>
    <time_frame>The first hospitalization period up to 19 weeks</time_frame>
    <description>The long term complications of prematurity (moderate-to-severe bronchopulmonary dysplasia (BPD), intraventricular hemorrhage gr 2-4, moderate to severe necrotizing enterocolitis, retinopathy of prematurity (ROP) needing therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term morbidity</measure>
    <time_frame>The first hospitalization period up to 19 weeks</time_frame>
    <description>Other long-term morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>The first hospitalization period up to 19 weeks</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prematurity; Extreme</condition>
  <condition>Low Birthweight, Extremely (999 Grams or Less)</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 10mg/mL infusion solution</intervention_name>
    <description>Intravenous paracetamol solution for infusion</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>acetaminophen</other_name>
    <other_name>Paracetamol Fresenius Kabi 10 mg/mL infusion solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Half physiological saline solution as the non-active placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Natriumklorid Braun 4,5mg/mL solution for infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infants born before 28+0 gestation weeks and/or birth weight less than 1000g

        Exclusion Criteria:

          -  Severe malformation or suspected chromosomal defect or other very severe
             life-threatening disease (e.g. very severe birth asphyxia or persistent pulmonary
             hypertension, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>96 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Outi Aikio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Outi Aikio, MD, PhD</last_name>
    <phone>+35883155810</phone>
    <email>outi.aikio@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aliisa Laitala, MD</last_name>
    <phone>+35883155823</phone>
    <email>aliisa.laitala@ppshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Outi Aikio, MD, PhD</last_name>
      <phone>+358 8 3155810</phone>
      <email>outi.aikio@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Outi Aikio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Harma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timo Saarela, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikko Hallman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aliisa Laitala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Juujärvi S, Saarela T, Hallman M, Aikio O. Intravenous paracetamol was associated with closure of the ductus arteriosus in extremely premature infants. Acta Paediatr. 2018 Apr;107(4):605-610. doi: 10.1111/apa.14137. Epub 2017 Nov 17.</citation>
    <PMID>29105147</PMID>
  </reference>
  <reference>
    <citation>Härkin P, Härmä A, Aikio O, Valkama M, Leskinen M, Saarela T, Hallman M. Paracetamol Accelerates Closure of the Ductus Arteriosus after Premature Birth: A Randomized Trial. J Pediatr. 2016 Oct;177:72-77.e2. doi: 10.1016/j.jpeds.2016.04.066. Epub 2016 May 20.</citation>
    <PMID>27215779</PMID>
  </reference>
  <reference>
    <citation>Härmä A, Aikio O, Hallman M, Saarela T. Intravenous Paracetamol Decreases Requirements of Morphine in Very Preterm Infants. J Pediatr. 2016 Jan;168:36-40. doi: 10.1016/j.jpeds.2015.08.003. Epub 2015 Aug 29.</citation>
    <PMID>26323200</PMID>
  </reference>
  <reference>
    <citation>Aikio O, Härkin P, Saarela T, Hallman M. Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants. J Matern Fetal Neonatal Med. 2014 Aug;27(12):1252-6. doi: 10.3109/14767058.2013.854327. Epub 2013 Oct 31.</citation>
    <PMID>24111688</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Outi Aikio</investigator_full_name>
    <investigator_title>MD, PhD, specialist in pediatrics and neonatology</investigator_title>
  </responsible_party>
  <keyword>acetaminophen</keyword>
  <keyword>ductus arteriosus</keyword>
  <keyword>NIRS</keyword>
  <keyword>intravenous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03641209/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

